Children with COVID-19 to be enrolled in remdesivir clinical trial, drugmaker says

Remdesivir has been shown to help adults with the coronavirus recover.
A vial of remdesivir at a Gilead manufacturing site in the United States
A vial of remdesivir at a Gilead manufacturing site in the United States.Gilead Sciences / via AP file

Breaking News Emails

Get breaking news alerts and special reports. The news and stories that matter, delivered weekday mornings.
By Reuters

Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderate-to-severe COVID-19 in a late-stage study testing its experimental drug, remdesivir.

The trial will assess the effectiveness and safety of the drug in the patients, which would include newborns to adolescents, across more than 30 sites in the United States and Europe, the company said.

Full coverage of the coronavirus outbreak

Gilead’s remdesivir, which has been at the forefront in the fight against the virus and has been given emergency use authorization in some countries, could be helpful in some patients after data showed it could shorten the time taken to recover from the disease.

The company is already running a late-stage study testing the drug in 6,000 patients with severe COVID-19.

Follow NBC HEALTH on Twitter & Facebook.